CSTL CASTLE BIOSCIENCES INC

CIK 0001447362 50 ready 8-Ks latest July 30, 2026, 4:06 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing July 30, 2026, 4:06 PM ET

Top materiality 0.85

Event mix earnings ×26 · other_material ×10 · other ×7

Sentiment 25 pos · 3 neg · 22 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CSTL

Highest-materiality recent filing

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.

Read filing →

July 30, 2026, 4:06 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M

Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.
May 6, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M

Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
February 26, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024

FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
January 13, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY

2025 total revenue >$340M, above guided range of $327-335M.
November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test

Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
August 4, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY

Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
May 5, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse

Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M

Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC

Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M

Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M

Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
February 28, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M

Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
January 8, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%

Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
November 2, 2023, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M

Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.
August 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M

Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).
May 3, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M

Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).
February 28, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M

Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.
January 9, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance

Total test reports in 2022: 44,338, up 58% YoY from 28,118.
November 2, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M

Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).
August 8, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M

Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.
May 9, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance

Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.
May 2, 2022, 7:59 PM ET M&A materiality 0.70 neutral item 3.02

Castle Biosciences completes AltheaDx acquisition; issues 763,887 shares

$65M initial consideration: $32.5M cash and $32.5M in stock (763,887 shares).
April 4, 2022, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 3.02 item 9.01

Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones

Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.
February 28, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M

Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.
January 14, 2022, 6:59 PM ET M&A materiality 0.60 positive item 9.01

Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout

Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.
January 10, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%

FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.
December 6, 2021, 6:59 PM ET M&A materiality 0.60 neutral item 1.01 item 2.01 item 9.01

Castle Biosciences completes acquisition of Cernostics for $30M upfront cash, up to $50M earnout

Acquisition closed December 3, 2021; upfront cash consideration approximately $30 million.
November 8, 2021, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics

Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.
October 19, 2021, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 7.01 item 8.01 item 9.01

Castle Biosciences to acquire Cernostics for up to $80M; expands into GI diagnostics with TissueCypher

Upfront consideration of $30M (cash or $20M cash + $10M stock at Castle's discretion); up to $50M in milestones based on 2022 performance.
August 9, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M

Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.

Executive changes

Departed

Mara G. Aspinall

Director

CSTL · CASTLE BIOSCIENCES INC

Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, Mara G. Aspinall notified the Company that she will not to stand for re-election to the board of directors (the “Board”) of the Company at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).

Appointed

Rodney Cotton

Class II Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2024-03-26
Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, following the recommendation of the nominating and corporate governance committee of the Board, the Board increased the size of the Board from eight to nine members and appointed Rodney Cotton to serve as a Class II director with a term ending at the 2024 Annual Meeting.

Departed

Bernhard E. Spiess

Chief Business Officer

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-12-31
Filed: January 5, 2022, 6:59 PM ET

Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.

Appointed

Kimberlee Caple

Class III Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

the Board appointed (i) Kimberlee Caple to serve as a Class III director until the Company’s 2022 annual meeting of stockholders

Appointed

Ellen Goldberg

Class I Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

and (ii) Ellen Goldberg to serve as a Class I director until the Company’s 2023 annual meeting of stockholders

Earnings & guidance

2026-Q1 EPS reported -$0.49 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

25 positive 3 negative 22 neutral

source · CSTL on sec.gov